Formosa Laboratories（4746）株式概要Formosa Laboratories, Inc.は、その子会社とともに、インド、オランダ、日本、ドイツ、台湾、中国、スイス、米国、カナダ、および国際的に医薬品原薬（API）および紫外線吸収剤を製造・販売している。 詳細4746 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績1/6財務の健全性6/6配当金4/6報酬株価収益率（ 13.2 x） TW市場（ 19.3 x）を下回っています。今年は黒字化を達成 リスク分析過去5年間で収益は年間20.8%減少しました。 財務結果に影響を与える大きな一時的項目 5.74%の配当はフリーキャッシュフローで十分にカバーされていない すべてのリスクチェックを見る4746 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW481,164 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA481,164 investors already sharing narrativesYour Fair ValueNT$Current PriceNT$52.3017.4% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-970m7b2016201920222025202620282031Revenue NT$7.4bEarnings NT$756.6mAdvancedSet Fair ValueView all narrativesFormosa Laboratories, Inc. 競合他社Savior LifetecSymbol: TPEX:4167Market cap: NT$6.4bSinphar PharmaceuticalLtdSymbol: TWSE:1734Market cap: NT$6.0bSCI PharmtechSymbol: TWSE:4119Market cap: NT$6.3bCenraSymbol: TWSE:3716Market cap: NT$5.0b価格と性能株価の高値、安値、推移の概要Formosa Laboratories過去の株価現在の株価NT$52.3052週高値NT$70.1052週安値NT$48.50ベータ0.481ヶ月の変化0.58%3ヶ月変化1.36%1年変化-20.27%3年間の変化-40.84%5年間の変化-21.59%IPOからの変化-43.09%最新ニュースUpcoming Dividend • Aug 17Upcoming dividend of NT$3.00 per shareEligible shareholders must have bought the stock before 24 August 2026. Payment date: 24 September 2026. Payout ratio is a comfortable 71% but the company is not cash flow positive. Trailing yield: 5.8%. Within top quartile of Taiwanese dividend payers (5.1%). Higher than average of industry peers (3.2%).Reported Earnings • Aug 15Second quarter 2026 earnings released: NT$0.12 loss per share (vs NT$1.26 loss in 2Q 2025)Second quarter 2026 results: NT$0.12 loss per share (improved from NT$1.26 loss in 2Q 2025). Revenue: NT$1.11b (down 11% from 2Q 2025). Net loss: NT$14.5m (loss narrowed 90% from 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.Buy Or Sell Opportunity • Aug 12Now 21% undervaluedThe stock has been flat over the last 90 days, currently trading at NT$53.60. The fair value is estimated to be NT$67.56, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years. Earnings per share has declined by 33%.Declared Dividend • Jul 31Dividend of NT$3.00 announcedShareholders will receive a dividend of NT$3.00. Ex-date: 24th August 2026 Payment date: 24th September 2026 Dividend yield will be 5.9%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is not covered by earnings (106% earnings payout ratio) nor is it covered by cash flows (318% cash payout ratio). The dividend has increased by an average of 4.2% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 18% to bring the payout ratio under control. However, EPS has declined by 28% over the last 5 years so the company would need to reverse this trend.Buy Or Sell Opportunity • Jul 14Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 1.5% to NT$52.30. The fair value is estimated to be NT$66.65, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years. Earnings per share has declined by 33%.Buy Or Sell Opportunity • May 18Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 8.5% to NT$51.90. The fair value is estimated to be NT$66.65, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years. Earnings per share has declined by 33%.最新情報をもっと見るRecent updatesUpcoming Dividend • Aug 17Upcoming dividend of NT$3.00 per shareEligible shareholders must have bought the stock before 24 August 2026. Payment date: 24 September 2026. Payout ratio is a comfortable 71% but the company is not cash flow positive. Trailing yield: 5.8%. Within top quartile of Taiwanese dividend payers (5.1%). Higher than average of industry peers (3.2%).Reported Earnings • Aug 15Second quarter 2026 earnings released: NT$0.12 loss per share (vs NT$1.26 loss in 2Q 2025)Second quarter 2026 results: NT$0.12 loss per share (improved from NT$1.26 loss in 2Q 2025). Revenue: NT$1.11b (down 11% from 2Q 2025). Net loss: NT$14.5m (loss narrowed 90% from 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.Buy Or Sell Opportunity • Aug 12Now 21% undervaluedThe stock has been flat over the last 90 days, currently trading at NT$53.60. The fair value is estimated to be NT$67.56, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years. Earnings per share has declined by 33%.Declared Dividend • Jul 31Dividend of NT$3.00 announcedShareholders will receive a dividend of NT$3.00. Ex-date: 24th August 2026 Payment date: 24th September 2026 Dividend yield will be 5.9%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is not covered by earnings (106% earnings payout ratio) nor is it covered by cash flows (318% cash payout ratio). The dividend has increased by an average of 4.2% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 18% to bring the payout ratio under control. However, EPS has declined by 28% over the last 5 years so the company would need to reverse this trend.Buy Or Sell Opportunity • Jul 14Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 1.5% to NT$52.30. The fair value is estimated to be NT$66.65, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years. Earnings per share has declined by 33%.Buy Or Sell Opportunity • May 18Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 8.5% to NT$51.90. The fair value is estimated to be NT$66.65, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years. Earnings per share has declined by 33%.Reported Earnings • May 16First quarter 2026 earnings released: EPS: NT$0.16 (vs NT$1.00 in 1Q 2025)First quarter 2026 results: EPS: NT$0.16 (down from NT$1.00 in 1Q 2025). Revenue: NT$1.06b (down 7.0% from 1Q 2025). Net income: NT$18.8m (down 84% from 1Q 2025). Profit margin: 1.8% (down from 11% in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.New Risk • Mar 31New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 27% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 29% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.お知らせ • Mar 13Formosa Laboratories, Inc., Annual General Meeting, Jun 24, 2026Formosa Laboratories, Inc., Annual General Meeting, Jun 24, 2026. Location: b1 floor no,108, sec.1 nan k`an rd., lujhu district, taoyuan city TaiwanReported Earnings • Mar 13Full year 2025 earnings released: EPS: NT$3.67 (vs NT$1.31 in FY 2024)Full year 2025 results: EPS: NT$3.67 (up from NT$1.31 in FY 2024). Revenue: NT$4.85b (up 2.5% from FY 2024). Net income: NT$441.1m (up 181% from FY 2024). Profit margin: 9.1% (up from 3.3% in FY 2024). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.Reported Earnings • Nov 15Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2025 results: EPS: NT$2.70 (up from NT$0.19 in 3Q 2024). Revenue: NT$1.16b (up 13% from 3Q 2024). Net income: NT$324.1m (up NT$301.7m from 3Q 2024). Profit margin: 28% (up from 2.2% in 3Q 2024). Revenue missed analyst estimates by 14%. Earnings per share (EPS) exceeded analyst estimates by 47%. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.Reported Earnings • Aug 17Second quarter 2025 earnings: EPS misses analyst expectationsSecond quarter 2025 results: NT$1.25 loss per share (down from NT$2.36 profit in 2Q 2024). Revenue: NT$1.24b (up 2.3% from 2Q 2024). Net loss: NT$150.9m (down 153% from profit in 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.New Risk • Aug 17New major risk - Revenue and earnings growthEarnings have declined by 27% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 27% per year over the past 5 years. Minor Risk Dividend is not well covered by earnings (97% payout ratio).Upcoming Dividend • Aug 14Upcoming dividend of NT$3.00 per shareEligible shareholders must have bought the stock before 21 August 2025. Payment date: 25 September 2025. Payout ratio is on the higher end at 97%, and the cash payout ratio is above 100%. Trailing yield: 4.3%. Lower than top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (2.5%).Declared Dividend • Jul 21Dividend of NT$3.00 announcedShareholders will receive a dividend of NT$3.00. Ex-date: 21st August 2025 Payment date: 25th September 2025 Dividend yield will be 4.4%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is not adequately covered by earnings (97% earnings payout ratio) nor is it covered by cash flows (124% cash payout ratio). The dividend has increased by an average of 4.1% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 7.2% to bring the payout ratio under control. However, EPS has declined by 19% over the last 5 years so the company would need to reverse this trend.Reported Earnings • May 11First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2025 results: EPS: NT$1.00 (up from NT$0.80 loss in 1Q 2024). Revenue: NT$1.14b (flat on 1Q 2024). Net income: NT$120.5m (up NT$216.6m from 1Q 2024). Profit margin: 11% (up from net loss in 1Q 2024). Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) missed analyst estimates by 5.7%. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.お知らせ • May 01Formosa Laboratories, Inc. to Report Q1, 2025 Results on May 08, 2025Formosa Laboratories, Inc. announced that they will report Q1, 2025 results on May 08, 2025Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$55.00, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 11x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 2.6% over the past three years.分析記事 • Mar 23Formosa Laboratories' (TWSE:4746) Strong Earnings Are Of Good QualityFormosa Laboratories, Inc. ( TWSE:4746 ) just reported healthy earnings but the stock price didn't move much. Our...Reported Earnings • Mar 14Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: EPS: NT$1.31 (up from NT$1.05 in FY 2023). Revenue: NT$4.73b (up 8.5% from FY 2023). Net income: NT$157.3m (up 25% from FY 2023). Profit margin: 3.3% (up from 2.9% in FY 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 78%. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 9% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Mar 13Formosa Laboratories, Inc., Annual General Meeting, Jun 20, 2025Formosa Laboratories, Inc., Annual General Meeting, Jun 20, 2025. Location: b1 floor no,108, sec.1 nan k`an rd., lujhu district, taoyuan city Taiwanお知らせ • Mar 06Formosa Laboratories, Inc. to Report Q4, 2024 Results on Mar 12, 2025Formosa Laboratories, Inc. announced that they will report Q4, 2024 results on Mar 12, 2025New Risk • Dec 07New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 138% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.4% per year over the past 5 years. Minor Risks Dividend is not well covered by cash flows (106% cash payout ratio). Large one-off items impacting financial results.Price Target Changed • Nov 26Price target decreased by 13% to NT$118Down from NT$135, the current price target is an average from 2 analysts. New target price is 50% above last closing price of NT$78.20. Stock is down 24% over the past year. The company is forecast to post earnings per share of NT$5.87 for next year compared to NT$1.05 last year.Reported Earnings • Nov 17Third quarter 2024 earnings released: EPS: NT$0.19 (vs NT$0.95 loss in 3Q 2023)Third quarter 2024 results: EPS: NT$0.19 (up from NT$0.95 loss in 3Q 2023). Revenue: NT$1.03b (down 8.7% from 3Q 2023). Net income: NT$22.4m (up NT$136.9m from 3Q 2023). Profit margin: 2.2% (up from net loss in 3Q 2023). The move to profitability was driven by lower expenses. Revenue is forecast to grow 9.3% p.a. on average during the next 2 years, compared to a 62% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings.お知らせ • Nov 07Formosa Laboratories, Inc. to Report Q3, 2024 Results on Nov 14, 2024Formosa Laboratories, Inc. announced that they will report Q3, 2024 results on Nov 14, 2024Valuation Update With 7 Day Price Move • Sep 23Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$104, the stock trades at a trailing P/E ratio of 48.9x. Average forward P/E is 18x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 78% over the past three years.分析記事 • Sep 20Risks To Shareholder Returns Are Elevated At These Prices For Formosa Laboratories, Inc. (TWSE:4746)With a price-to-earnings (or "P/E") ratio of 46.7x Formosa Laboratories, Inc. ( TWSE:4746 ) may be sending very bearish...Reported Earnings • Aug 13Second quarter 2024 earnings released: EPS: NT$2.36 (vs NT$0.69 in 2Q 2023)Second quarter 2024 results: EPS: NT$2.36 (up from NT$0.69 in 2Q 2023). Revenue: NT$1.21b (up 12% from 2Q 2023). Net income: NT$283.9m (up 240% from 2Q 2023). Profit margin: 23% (up from 7.7% in 2Q 2023). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 41% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.お知らせ • Aug 03Formosa Laboratories, Inc. to Report Q2, 2024 Results on Aug 09, 2024Formosa Laboratories, Inc. announced that they will report Q2, 2024 results on Aug 09, 2024Declared Dividend • Jul 29Dividend increased to NT$2.00Dividend of NT$2.00 is 100% higher than last year. Ex-date: 13th August 2024 Payment date: 12th September 2024 Dividend yield will be 1.9%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is not covered by earnings (434% earnings payout ratio). However, it is covered by cash flows (60% cash payout ratio). The dividend has remained flat since 9 years ago. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 382% to bring the payout ratio under control, which is more than the 3.3% EPS growth achieved over the last 5 years.お知らせ • Jul 27Formosa Laboratories, Inc. Announces Common Stock Dividend Distribution, Payable on September 12, 2024Formosa Laboratories, Inc. announced the ex-dividend record date of cash dividends. Type and monetary amount of common stock dividend distribution: Cash dividends is TWD 240,511,926 (TWD 2 per share). Ex-rights (ex-dividend) trading date is August 13, 2024. Ex-rights (ex-dividend) record date is August 19, 2024. Payment date of common stock cash dividend distribution is September 12, 2024.お知らせ • Jun 05Formosa Laboratories, Inc. (TWSE : 4746) acquired SynChem, Inc.Formosa Laboratories, Inc. (TWSE : 4746) acquired SynChem, Inc. on June 3, 2024. SynChem will now operate under the new name SynChem-Formosa. As a now wholly-owned subsidiary of Formosa Laboratories, Dr. W. Paul Mar will continue as CEO of SynChem-Formosa, leading the company's operations and reporting directly to Dr. Cheng, Chairman and President of Formosa. Formosa Laboratories, Inc. (TWSE : 4746) completed the acquisition of SynChem, Inc. on June 3, 2024.分析記事 • May 22Investors Can Find Comfort In Formosa Laboratories' (TWSE:4746) Earnings QualityInvestors were disappointed with the weak earnings posted by Formosa Laboratories, Inc. ( TWSE:4746 ). Despite the soft...Reported Earnings • May 18First quarter 2024 earnings released: NT$0.80 loss per share (vs NT$0.21 loss in 1Q 2023)First quarter 2024 results: NT$0.80 loss per share (further deteriorated from NT$0.21 loss in 1Q 2023). Revenue: NT$1.13b (up 22% from 1Q 2023). Net loss: NT$96.0m (loss widened 282% from 1Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 34% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.お知らせ • May 02Formosa Laboratories, Inc. to Report Q1, 2024 Results on May 09, 2024Formosa Laboratories, Inc. announced that they will report Q1, 2024 results on May 09, 2024分析記事 • Apr 19Benign Growth For Formosa Laboratories, Inc. (TWSE:4746) Underpins Its Share PriceYou may think that with a price-to-sales (or "P/S") ratio of 2.8x Formosa Laboratories, Inc. ( TWSE:4746 ) is a stock...お知らせ • Mar 13Formosa Laboratories, Inc., Annual General Meeting, Jun 25, 2024Formosa Laboratories, Inc., Annual General Meeting, Jun 25, 2024. Location: Monarch Skyline Hotel B1 Purple Cloud Hall 2 located at No.108, Sec 1, Nankan Rd, Luzhu Dist., Taoyuan City 338 Taoyuan City Taiwan Agenda: to consider 2023 business report; to consider audit committee's review report on 2023 financial results; to consider 2023 employees' and directors' remuneration distribution; to consider 2023 directors' remuneration report; to consider 2023 business report and financial statements; to consider 2023 earnings distribution; to authorize the board of directors to handle matters related of the cash capital increase of Formosa pharmaceuticals inc. within the next year; to consider the directors and their representatives from non-competition restrictions; and to consider other issues.Reported Earnings • Mar 13Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: EPS: NT$1.05 (down from NT$3.40 in FY 2022). Revenue: NT$4.36b (up 16% from FY 2022). Net income: NT$126.2m (down 69% from FY 2022). Profit margin: 2.9% (down from 11% in FY 2022). Revenue missed analyst estimates by 4.9%. Earnings per share (EPS) also missed analyst estimates by 74%. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 33% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Jan 19Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$117, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 15x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 184% over the past three years.New Risk • Nov 30New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 67% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Nov 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to NT$99.00, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 15x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 108% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at NT$62.50 per share.お知らせ • Nov 12Formosa Laboratories, Inc. Announces Change of Members of the Sustainable Development CommitteeFormosa Laboratories, Inc. announced change of members of the Sustainable Development Committee. Name of the previous position holder: Cheng Chen-Yu; Yang Chih-Ping; Wang Szu-Ching. Resume of the previous position holder: Cheng Chen-Yu/Chairman & President, Formosa Laboratories, Inc.; Yang Chih-Ping/Chief Executive Officer, Formosa Laboratories, Inc. and Wang Szu-Ching/Vice President of EN & SHE, Formosa Laboratories, Inc. Name of the new position holder: Cheng Chen-Yu; Lu Ta-Jung and Chaung Tza-Zen. Resume of the new position holder: Cheng Chen-Yu/Chairman & President, Formosa Laboratories, Inc. Lu Ta-Jung/Independent director of Formosa Laboratories, Inc. Chaung Tza-Ze/Independent director of Formosa Laboratories, Inc. Effective date of the new member is November 10, 2023.Upcoming Dividend • Aug 17Upcoming dividend of NT$1.00 per share at 1.2% yieldEligible shareholders must have bought the stock before 24 August 2023. Payment date: 22 September 2023. Payout ratio is a comfortable 14% but the company is paying out more than the cash it is generating. Trailing yield: 1.2%. Lower than top quartile of Taiwanese dividend payers (5.7%). Lower than average of industry peers (1.6%).Reported Earnings • Aug 15Second quarter 2023 earnings released: EPS: NT$0.69 (vs NT$0.071 loss in 2Q 2022)Second quarter 2023 results: EPS: NT$0.69 (up from NT$0.071 loss in 2Q 2022). Revenue: NT$1.09b (up 30% from 2Q 2022). Net income: NT$83.4m (up NT$91.9m from 2Q 2022). Profit margin: 7.7% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 63% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.お知らせ • Aug 11Formosa Laboratories, Inc. Appoints Lin Chien-Fei as Chief Information Security OfficerFormosa Laboratories, Inc. appointed Lin Chien-Fei/Assistant Vice President of Information Technology as Chief Information Security Officer. Effective date: August 10, 2023.お知らせ • Aug 05Formosa Laboratories, Inc. Announces Cash Dividend, Payable on September 22, 2023Formosa Laboratories, Inc. announced cash dividend of TWD 120,255,963 (TWD 1 per share) of common stock. Ex-rights (ex-dividend) trading date is August 24, 2023; Ex-rights (ex-dividend) record date is September 01, 2023; Payment date of cash dividend distribution is September 22, 2023.お知らせ • Jun 28Formosa Laboratories, Inc. Approves Independent Directors ElectionsFormosa Laboratories, Inc. announced at annual shareholders meeting held on June 27, 2023, the shareholders approved election of Chaung,Tza-Zen and Chang,Ting-Jung as independent directors of the company.Valuation Update With 7 Day Price Move • May 02Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$91.50, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 57% over the past three years.Reported Earnings • Mar 17Full year 2022 earnings released: EPS: NT$3.40 (vs NT$10.92 in FY 2021)Full year 2022 results: EPS: NT$3.40 (down from NT$10.92 in FY 2021). Revenue: NT$3.77b (up 20% from FY 2021). Net income: NT$409.4m (down 67% from FY 2021). Profit margin: 11% (down from 40% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 9 highly experienced directors. 1 independent director (6 non-independent directors). Independent Director Zhe Ren Zhuang was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Nov 13Third quarter 2022 earnings released: EPS: NT$4.09 (vs NT$3.20 loss in 3Q 2021)Third quarter 2022 results: EPS: NT$4.09 (up from NT$3.20 loss in 3Q 2021). Revenue: NT$1.02b (up 49% from 3Q 2021). Net income: NT$492.1m (up NT$876.6m from 3Q 2021). Profit margin: 48% (up from net loss in 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.Reported Earnings • Aug 17Second quarter 2022 earnings released: NT$0.07 loss per share (vs NT$6.86 profit in 2Q 2021)Second quarter 2022 results: NT$0.07 loss per share (down from NT$6.86 profit in 2Q 2021). Revenue: NT$838.2m (up 1.3% from 2Q 2021). Net loss: NT$8.53m (down 101% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 17% per year.Upcoming Dividend • Jul 20Upcoming dividend of NT$2.00 per shareEligible shareholders must have bought the stock before 27 July 2022. Payment date: 25 August 2022. Trailing yield: 4.2%. Lower than top quartile of Taiwanese dividend payers (6.8%). Higher than average of industry peers (2.9%).Reported Earnings • May 16First quarter 2022 earnings released: NT$3.33 loss per share (vs NT$9.84 profit in 1Q 2021)First quarter 2022 results: NT$3.33 loss per share (down from NT$9.84 profit in 1Q 2021). Revenue: NT$834.9m (up 13% from 1Q 2021). Net loss: NT$400.4m (down 138% from profit in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.Price Target Changed • Apr 27Price target decreased to NT$55.00Down from NT$65.00, the current price target is provided by 1 analyst. New target price is 15% below last closing price of NT$64.90. Stock is up 13% over the past year. The company posted earnings per share of NT$10.92 last year.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 9 highly experienced directors. 1 independent director (6 non-independent directors). Independent Director Zhe Ren Zhuang was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improved over the past weekAfter last week's 18% share price gain to NT$68.10, the stock trades at a trailing P/E ratio of 6.6x. Average forward P/E is 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 61% over the past three years.Reported Earnings • Mar 13Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: NT$10.92 (up from NT$3.79 in FY 2020). Revenue: NT$3.14b (up 2.2% from FY 2020). Net income: NT$1.25b (up 212% from FY 2020). Profit margin: 40% (up from 13% in FY 2020). The increase in margin was primarily driven by lower expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 12Third quarter 2021 earnings released: NT$3.20 loss per share (vs NT$0.93 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: NT$689.7m (down 15% from 3Q 2020). Net loss: NT$384.6m (down 481% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 09Second quarter 2021 earnings released: EPS NT$6.86 (vs NT$4.99 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: NT$827.3m (up 5.0% from 2Q 2020). Net income: NT$744.6m (up 39% from 2Q 2020). Profit margin: 90% (up from 68% in 2Q 2020). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Jul 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to NT$66.80, the stock trades at a trailing P/E ratio of 4.6x. Average forward P/E is 21x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 30% over the past three years.Valuation Update With 7 Day Price Move • Jun 17Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to NT$83.60, the stock trades at a trailing P/E ratio of 5.8x. Average forward P/E is 20x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 60% over the past three years.Valuation Update With 7 Day Price Move • May 21Investor sentiment improved over the past weekAfter last week's 28% share price gain to NT$74.40, the stock trades at a trailing P/E ratio of 5.1x. Average forward P/E is 20x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 41% over the past three years.Reported Earnings • May 15First quarter 2021 earnings released: EPS NT$9.84 (vs NT$1.03 loss in 1Q 2020)First quarter 2021 results: Revenue: NT$736.3m (up 11% from 1Q 2020). Net income: NT$1.07b (up NT$1.17b from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.分析記事 • Apr 19Here's Why Formosa Laboratories (TPE:4746) Has A Meaningful Debt BurdenHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Valuation Update With 7 Day Price Move • Mar 23Investor sentiment improved over the past weekAfter last week's 15% share price gain to NT$56.60, the stock trades at a forward P/E ratio of 74x. Average forward P/E is 22x in the Pharmaceuticals industry in Taiwan. Total loss to shareholders of 2.9% over the past three years.分析記事 • Mar 16Does Formosa Laboratories, Inc.'s (TPE:4746) Weak Fundamentals Mean A Downturn In Its Stock Should Be Expected?Formosa Laboratories' (TPE:4746) stock is up by 9.9% over the past three months. However, in this article, we decided...Reported Earnings • Mar 06Full year 2020 earnings released: EPS NT$3.78 (vs NT$0.12 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$3.08b (up 11% from FY 2019). Net income: NT$400.0m (up NT$388.4m from FY 2019). Profit margin: 13% (up from 0.4% in FY 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Feb 22Investor sentiment improved over the past weekAfter last week's 16% share price gain to NT$54.80, the stock is trading at a trailing P/E ratio of 12.3x, up from the previous P/E ratio of 10.6x. This compares to an average P/E of 18x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders over the past three years are 8.7%.Is New 90 Day High Low • Feb 19New 90-day high: NT$52.80The company is up 6.0% from its price of NT$49.90 on 20 November 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 13% over the same period.分析記事 • Feb 08What Type Of Returns Would Formosa Laboratories'(TPE:4746) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?The main aim of stock picking is to find the market-beating stocks. But in any portfolio, there will be mixed results...分析記事 • Jan 11Formosa Laboratories (TPE:4746) Is Making Moderate Use Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Dec 13Formosa Laboratories's (TPE:4746) Earnings Are Growing But Is There More To The Story?Many investors consider it preferable to invest in profitable companies over unprofitable ones, because profitability...Is New 90 Day High Low • Dec 07New 90-day low: NT$47.80The company is down 10.0% from its price of NT$53.20 on 08 September 2020. The Taiwanese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 7.0% over the same period.Reported Earnings • Nov 15Third quarter 2020 earnings released: EPS NT$0.93The company reported a soft third quarter result with weaker earnings and profit margins, although revenues were improved. Third quarter 2020 results: Revenue: NT$814.7m (up 3.2% from 3Q 2019). Net income: NT$100.9m (down 41% from 3Q 2019). Profit margin: 12% (down from 22% in 3Q 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 13% per year whereas the company’s share price has fallen by 11% per year.Is New 90 Day High Low • Oct 28New 90-day low: NT$48.40The company is down 3.0% from its price of NT$50.10 on 30 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period.株主還元4746TW PharmaceuticalsTW 市場7D-4.9%-3.6%2.0%1Y-20.3%-22.7%85.1%株主還元を見る業界別リターン: 4746過去 1 年間で-22.7 % の収益を上げたTW Pharmaceuticals業界を上回りました。リターン対市場: 4746は、過去 1 年間で85.1 % のリターンを上げたTW市場を下回りました。価格変動Is 4746's price volatile compared to industry and market?4746 volatility4746 Average Weekly Movement3.8%Pharmaceuticals Industry Average Movement5.2%Market Average Movement6.4%10% most volatile stocks in TW Market12.0%10% least volatile stocks in TW Market2.7%安定した株価: 4746 、 TW市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 4746の 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1985n/aChen-Yu Chengwww.formosalab.comFormosa Laboratories, Inc.は、子会社とともに、インド、オランダ、日本、ドイツ、台湾、中国、スイス、米国、カナダ、および国際的に医薬品原薬（API）および紫外線吸収剤を製造・販売している。抗がん剤、ビタミンD誘導体、抗炎症・鎮痛剤、免疫調節剤、呼吸器官用剤、コレステロール・リン酸結合剤、UVフィルター、鉄欠乏性貧血（IDA）、中枢神経系用剤、MRI増強剤、ステロイド、抗生物質などの分野の原薬を、IDA、MRI用剤、腫瘍学などの分野の注射剤を提供している。また、再結晶、ろ過、透析、カラム精製、蒸留、噴霧乾燥、微粒化などの受託開発・製造サービス、注射剤製造および二次包装、ラベル付け、シリアル化サービス、カスタム発酵サービス、ペプチド合成サービスなども提供している。さらに、抗体医薬コンジュゲートサービスとして、抗体開発・製造、ペプチド・ポリマー医薬コンジュゲーション、リンカーペイロード設計・合成・製造、バイオコンジュゲーション・精製、細胞毒性液体充填・凍結乾燥製品のプレフォーミュレーション研究～製造、薬事サポートなどを提供している。さらに、化学品の取引や投資活動にも携わっている。フォルモサ・ラボラトリーズ・インクは1985年に設立され、台湾の桃園に本社を置いている。もっと見るFormosa Laboratories, Inc. 基礎のまとめFormosa Laboratories の収益と売上を時価総額と比較するとどうか。4746 基礎統計学時価総額NT$6.29b収益（TTM）NT$475.70m売上高(TTM)NT$4.64b13.2xPER（株価収益率1.4xP/Sレシオ4746 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計4746 損益計算書（TTM）収益NT$4.64b売上原価NT$2.71b売上総利益NT$1.93bその他の費用NT$1.45b収益NT$475.70m直近の収益報告Jun 30, 2026次回決算日該当なし一株当たり利益（EPS）3.96グロス・マージン41.50%純利益率10.25%有利子負債／自己資本比率37.3%4746 の長期的なパフォーマンスは？過去の実績と比較を見る配当金5.7%現在の配当利回り71%配当性向4746 配当は確実ですか？4746 配当履歴とベンチマークを見る4746 、いつまでに購入すれば配当金を受け取れますか？Formosa Laboratories 配当日配当落ち日Aug 24 2026配当支払日Sep 24 2026配当落ちまでの日数5 days配当支払日までの日数36 days4746 配当は確実ですか？4746 配当履歴とベンチマークを見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/18 19:13終値2026/08/18 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Formosa Laboratories, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関null nullKGI Securities Co. Ltd.Hsuan ChenKGI Securities Co. Ltd.Xiaowei HuangMasterlink Securities Investment Advisory1 その他のアナリストを表示
Upcoming Dividend • Aug 17Upcoming dividend of NT$3.00 per shareEligible shareholders must have bought the stock before 24 August 2026. Payment date: 24 September 2026. Payout ratio is a comfortable 71% but the company is not cash flow positive. Trailing yield: 5.8%. Within top quartile of Taiwanese dividend payers (5.1%). Higher than average of industry peers (3.2%).
Reported Earnings • Aug 15Second quarter 2026 earnings released: NT$0.12 loss per share (vs NT$1.26 loss in 2Q 2025)Second quarter 2026 results: NT$0.12 loss per share (improved from NT$1.26 loss in 2Q 2025). Revenue: NT$1.11b (down 11% from 2Q 2025). Net loss: NT$14.5m (loss narrowed 90% from 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.
Buy Or Sell Opportunity • Aug 12Now 21% undervaluedThe stock has been flat over the last 90 days, currently trading at NT$53.60. The fair value is estimated to be NT$67.56, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years. Earnings per share has declined by 33%.
Declared Dividend • Jul 31Dividend of NT$3.00 announcedShareholders will receive a dividend of NT$3.00. Ex-date: 24th August 2026 Payment date: 24th September 2026 Dividend yield will be 5.9%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is not covered by earnings (106% earnings payout ratio) nor is it covered by cash flows (318% cash payout ratio). The dividend has increased by an average of 4.2% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 18% to bring the payout ratio under control. However, EPS has declined by 28% over the last 5 years so the company would need to reverse this trend.
Buy Or Sell Opportunity • Jul 14Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 1.5% to NT$52.30. The fair value is estimated to be NT$66.65, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years. Earnings per share has declined by 33%.
Buy Or Sell Opportunity • May 18Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 8.5% to NT$51.90. The fair value is estimated to be NT$66.65, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years. Earnings per share has declined by 33%.
Upcoming Dividend • Aug 17Upcoming dividend of NT$3.00 per shareEligible shareholders must have bought the stock before 24 August 2026. Payment date: 24 September 2026. Payout ratio is a comfortable 71% but the company is not cash flow positive. Trailing yield: 5.8%. Within top quartile of Taiwanese dividend payers (5.1%). Higher than average of industry peers (3.2%).
Reported Earnings • Aug 15Second quarter 2026 earnings released: NT$0.12 loss per share (vs NT$1.26 loss in 2Q 2025)Second quarter 2026 results: NT$0.12 loss per share (improved from NT$1.26 loss in 2Q 2025). Revenue: NT$1.11b (down 11% from 2Q 2025). Net loss: NT$14.5m (loss narrowed 90% from 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.
Buy Or Sell Opportunity • Aug 12Now 21% undervaluedThe stock has been flat over the last 90 days, currently trading at NT$53.60. The fair value is estimated to be NT$67.56, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years. Earnings per share has declined by 33%.
Declared Dividend • Jul 31Dividend of NT$3.00 announcedShareholders will receive a dividend of NT$3.00. Ex-date: 24th August 2026 Payment date: 24th September 2026 Dividend yield will be 5.9%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is not covered by earnings (106% earnings payout ratio) nor is it covered by cash flows (318% cash payout ratio). The dividend has increased by an average of 4.2% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 18% to bring the payout ratio under control. However, EPS has declined by 28% over the last 5 years so the company would need to reverse this trend.
Buy Or Sell Opportunity • Jul 14Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 1.5% to NT$52.30. The fair value is estimated to be NT$66.65, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years. Earnings per share has declined by 33%.
Buy Or Sell Opportunity • May 18Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 8.5% to NT$51.90. The fair value is estimated to be NT$66.65, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years. Earnings per share has declined by 33%.
Reported Earnings • May 16First quarter 2026 earnings released: EPS: NT$0.16 (vs NT$1.00 in 1Q 2025)First quarter 2026 results: EPS: NT$0.16 (down from NT$1.00 in 1Q 2025). Revenue: NT$1.06b (down 7.0% from 1Q 2025). Net income: NT$18.8m (down 84% from 1Q 2025). Profit margin: 1.8% (down from 11% in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
New Risk • Mar 31New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 27% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 29% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.
お知らせ • Mar 13Formosa Laboratories, Inc., Annual General Meeting, Jun 24, 2026Formosa Laboratories, Inc., Annual General Meeting, Jun 24, 2026. Location: b1 floor no,108, sec.1 nan k`an rd., lujhu district, taoyuan city Taiwan
Reported Earnings • Mar 13Full year 2025 earnings released: EPS: NT$3.67 (vs NT$1.31 in FY 2024)Full year 2025 results: EPS: NT$3.67 (up from NT$1.31 in FY 2024). Revenue: NT$4.85b (up 2.5% from FY 2024). Net income: NT$441.1m (up 181% from FY 2024). Profit margin: 9.1% (up from 3.3% in FY 2024). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
Reported Earnings • Nov 15Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2025 results: EPS: NT$2.70 (up from NT$0.19 in 3Q 2024). Revenue: NT$1.16b (up 13% from 3Q 2024). Net income: NT$324.1m (up NT$301.7m from 3Q 2024). Profit margin: 28% (up from 2.2% in 3Q 2024). Revenue missed analyst estimates by 14%. Earnings per share (EPS) exceeded analyst estimates by 47%. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
Reported Earnings • Aug 17Second quarter 2025 earnings: EPS misses analyst expectationsSecond quarter 2025 results: NT$1.25 loss per share (down from NT$2.36 profit in 2Q 2024). Revenue: NT$1.24b (up 2.3% from 2Q 2024). Net loss: NT$150.9m (down 153% from profit in 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
New Risk • Aug 17New major risk - Revenue and earnings growthEarnings have declined by 27% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 27% per year over the past 5 years. Minor Risk Dividend is not well covered by earnings (97% payout ratio).
Upcoming Dividend • Aug 14Upcoming dividend of NT$3.00 per shareEligible shareholders must have bought the stock before 21 August 2025. Payment date: 25 September 2025. Payout ratio is on the higher end at 97%, and the cash payout ratio is above 100%. Trailing yield: 4.3%. Lower than top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (2.5%).
Declared Dividend • Jul 21Dividend of NT$3.00 announcedShareholders will receive a dividend of NT$3.00. Ex-date: 21st August 2025 Payment date: 25th September 2025 Dividend yield will be 4.4%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is not adequately covered by earnings (97% earnings payout ratio) nor is it covered by cash flows (124% cash payout ratio). The dividend has increased by an average of 4.1% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 7.2% to bring the payout ratio under control. However, EPS has declined by 19% over the last 5 years so the company would need to reverse this trend.
Reported Earnings • May 11First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2025 results: EPS: NT$1.00 (up from NT$0.80 loss in 1Q 2024). Revenue: NT$1.14b (flat on 1Q 2024). Net income: NT$120.5m (up NT$216.6m from 1Q 2024). Profit margin: 11% (up from net loss in 1Q 2024). Revenue exceeded analyst estimates by 14%. Earnings per share (EPS) missed analyst estimates by 5.7%. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
お知らせ • May 01Formosa Laboratories, Inc. to Report Q1, 2025 Results on May 08, 2025Formosa Laboratories, Inc. announced that they will report Q1, 2025 results on May 08, 2025
Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$55.00, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 11x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 2.6% over the past three years.
分析記事 • Mar 23Formosa Laboratories' (TWSE:4746) Strong Earnings Are Of Good QualityFormosa Laboratories, Inc. ( TWSE:4746 ) just reported healthy earnings but the stock price didn't move much. Our...
Reported Earnings • Mar 14Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: EPS: NT$1.31 (up from NT$1.05 in FY 2023). Revenue: NT$4.73b (up 8.5% from FY 2023). Net income: NT$157.3m (up 25% from FY 2023). Profit margin: 3.3% (up from 2.9% in FY 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 78%. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 9% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Mar 13Formosa Laboratories, Inc., Annual General Meeting, Jun 20, 2025Formosa Laboratories, Inc., Annual General Meeting, Jun 20, 2025. Location: b1 floor no,108, sec.1 nan k`an rd., lujhu district, taoyuan city Taiwan
お知らせ • Mar 06Formosa Laboratories, Inc. to Report Q4, 2024 Results on Mar 12, 2025Formosa Laboratories, Inc. announced that they will report Q4, 2024 results on Mar 12, 2025
New Risk • Dec 07New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 138% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.4% per year over the past 5 years. Minor Risks Dividend is not well covered by cash flows (106% cash payout ratio). Large one-off items impacting financial results.
Price Target Changed • Nov 26Price target decreased by 13% to NT$118Down from NT$135, the current price target is an average from 2 analysts. New target price is 50% above last closing price of NT$78.20. Stock is down 24% over the past year. The company is forecast to post earnings per share of NT$5.87 for next year compared to NT$1.05 last year.
Reported Earnings • Nov 17Third quarter 2024 earnings released: EPS: NT$0.19 (vs NT$0.95 loss in 3Q 2023)Third quarter 2024 results: EPS: NT$0.19 (up from NT$0.95 loss in 3Q 2023). Revenue: NT$1.03b (down 8.7% from 3Q 2023). Net income: NT$22.4m (up NT$136.9m from 3Q 2023). Profit margin: 2.2% (up from net loss in 3Q 2023). The move to profitability was driven by lower expenses. Revenue is forecast to grow 9.3% p.a. on average during the next 2 years, compared to a 62% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings.
お知らせ • Nov 07Formosa Laboratories, Inc. to Report Q3, 2024 Results on Nov 14, 2024Formosa Laboratories, Inc. announced that they will report Q3, 2024 results on Nov 14, 2024
Valuation Update With 7 Day Price Move • Sep 23Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$104, the stock trades at a trailing P/E ratio of 48.9x. Average forward P/E is 18x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 78% over the past three years.
分析記事 • Sep 20Risks To Shareholder Returns Are Elevated At These Prices For Formosa Laboratories, Inc. (TWSE:4746)With a price-to-earnings (or "P/E") ratio of 46.7x Formosa Laboratories, Inc. ( TWSE:4746 ) may be sending very bearish...
Reported Earnings • Aug 13Second quarter 2024 earnings released: EPS: NT$2.36 (vs NT$0.69 in 2Q 2023)Second quarter 2024 results: EPS: NT$2.36 (up from NT$0.69 in 2Q 2023). Revenue: NT$1.21b (up 12% from 2Q 2023). Net income: NT$283.9m (up 240% from 2Q 2023). Profit margin: 23% (up from 7.7% in 2Q 2023). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 41% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
お知らせ • Aug 03Formosa Laboratories, Inc. to Report Q2, 2024 Results on Aug 09, 2024Formosa Laboratories, Inc. announced that they will report Q2, 2024 results on Aug 09, 2024
Declared Dividend • Jul 29Dividend increased to NT$2.00Dividend of NT$2.00 is 100% higher than last year. Ex-date: 13th August 2024 Payment date: 12th September 2024 Dividend yield will be 1.9%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is not covered by earnings (434% earnings payout ratio). However, it is covered by cash flows (60% cash payout ratio). The dividend has remained flat since 9 years ago. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 382% to bring the payout ratio under control, which is more than the 3.3% EPS growth achieved over the last 5 years.
お知らせ • Jul 27Formosa Laboratories, Inc. Announces Common Stock Dividend Distribution, Payable on September 12, 2024Formosa Laboratories, Inc. announced the ex-dividend record date of cash dividends. Type and monetary amount of common stock dividend distribution: Cash dividends is TWD 240,511,926 (TWD 2 per share). Ex-rights (ex-dividend) trading date is August 13, 2024. Ex-rights (ex-dividend) record date is August 19, 2024. Payment date of common stock cash dividend distribution is September 12, 2024.
お知らせ • Jun 05Formosa Laboratories, Inc. (TWSE : 4746) acquired SynChem, Inc.Formosa Laboratories, Inc. (TWSE : 4746) acquired SynChem, Inc. on June 3, 2024. SynChem will now operate under the new name SynChem-Formosa. As a now wholly-owned subsidiary of Formosa Laboratories, Dr. W. Paul Mar will continue as CEO of SynChem-Formosa, leading the company's operations and reporting directly to Dr. Cheng, Chairman and President of Formosa. Formosa Laboratories, Inc. (TWSE : 4746) completed the acquisition of SynChem, Inc. on June 3, 2024.
分析記事 • May 22Investors Can Find Comfort In Formosa Laboratories' (TWSE:4746) Earnings QualityInvestors were disappointed with the weak earnings posted by Formosa Laboratories, Inc. ( TWSE:4746 ). Despite the soft...
Reported Earnings • May 18First quarter 2024 earnings released: NT$0.80 loss per share (vs NT$0.21 loss in 1Q 2023)First quarter 2024 results: NT$0.80 loss per share (further deteriorated from NT$0.21 loss in 1Q 2023). Revenue: NT$1.13b (up 22% from 1Q 2023). Net loss: NT$96.0m (loss widened 282% from 1Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 34% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
お知らせ • May 02Formosa Laboratories, Inc. to Report Q1, 2024 Results on May 09, 2024Formosa Laboratories, Inc. announced that they will report Q1, 2024 results on May 09, 2024
分析記事 • Apr 19Benign Growth For Formosa Laboratories, Inc. (TWSE:4746) Underpins Its Share PriceYou may think that with a price-to-sales (or "P/S") ratio of 2.8x Formosa Laboratories, Inc. ( TWSE:4746 ) is a stock...
お知らせ • Mar 13Formosa Laboratories, Inc., Annual General Meeting, Jun 25, 2024Formosa Laboratories, Inc., Annual General Meeting, Jun 25, 2024. Location: Monarch Skyline Hotel B1 Purple Cloud Hall 2 located at No.108, Sec 1, Nankan Rd, Luzhu Dist., Taoyuan City 338 Taoyuan City Taiwan Agenda: to consider 2023 business report; to consider audit committee's review report on 2023 financial results; to consider 2023 employees' and directors' remuneration distribution; to consider 2023 directors' remuneration report; to consider 2023 business report and financial statements; to consider 2023 earnings distribution; to authorize the board of directors to handle matters related of the cash capital increase of Formosa pharmaceuticals inc. within the next year; to consider the directors and their representatives from non-competition restrictions; and to consider other issues.
Reported Earnings • Mar 13Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: EPS: NT$1.05 (down from NT$3.40 in FY 2022). Revenue: NT$4.36b (up 16% from FY 2022). Net income: NT$126.2m (down 69% from FY 2022). Profit margin: 2.9% (down from 11% in FY 2022). Revenue missed analyst estimates by 4.9%. Earnings per share (EPS) also missed analyst estimates by 74%. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 33% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Jan 19Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$117, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 15x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 184% over the past three years.
New Risk • Nov 30New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 67% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Nov 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to NT$99.00, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 15x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 108% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at NT$62.50 per share.
お知らせ • Nov 12Formosa Laboratories, Inc. Announces Change of Members of the Sustainable Development CommitteeFormosa Laboratories, Inc. announced change of members of the Sustainable Development Committee. Name of the previous position holder: Cheng Chen-Yu; Yang Chih-Ping; Wang Szu-Ching. Resume of the previous position holder: Cheng Chen-Yu/Chairman & President, Formosa Laboratories, Inc.; Yang Chih-Ping/Chief Executive Officer, Formosa Laboratories, Inc. and Wang Szu-Ching/Vice President of EN & SHE, Formosa Laboratories, Inc. Name of the new position holder: Cheng Chen-Yu; Lu Ta-Jung and Chaung Tza-Zen. Resume of the new position holder: Cheng Chen-Yu/Chairman & President, Formosa Laboratories, Inc. Lu Ta-Jung/Independent director of Formosa Laboratories, Inc. Chaung Tza-Ze/Independent director of Formosa Laboratories, Inc. Effective date of the new member is November 10, 2023.
Upcoming Dividend • Aug 17Upcoming dividend of NT$1.00 per share at 1.2% yieldEligible shareholders must have bought the stock before 24 August 2023. Payment date: 22 September 2023. Payout ratio is a comfortable 14% but the company is paying out more than the cash it is generating. Trailing yield: 1.2%. Lower than top quartile of Taiwanese dividend payers (5.7%). Lower than average of industry peers (1.6%).
Reported Earnings • Aug 15Second quarter 2023 earnings released: EPS: NT$0.69 (vs NT$0.071 loss in 2Q 2022)Second quarter 2023 results: EPS: NT$0.69 (up from NT$0.071 loss in 2Q 2022). Revenue: NT$1.09b (up 30% from 2Q 2022). Net income: NT$83.4m (up NT$91.9m from 2Q 2022). Profit margin: 7.7% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 63% growth forecast for the Pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.
お知らせ • Aug 11Formosa Laboratories, Inc. Appoints Lin Chien-Fei as Chief Information Security OfficerFormosa Laboratories, Inc. appointed Lin Chien-Fei/Assistant Vice President of Information Technology as Chief Information Security Officer. Effective date: August 10, 2023.
お知らせ • Aug 05Formosa Laboratories, Inc. Announces Cash Dividend, Payable on September 22, 2023Formosa Laboratories, Inc. announced cash dividend of TWD 120,255,963 (TWD 1 per share) of common stock. Ex-rights (ex-dividend) trading date is August 24, 2023; Ex-rights (ex-dividend) record date is September 01, 2023; Payment date of cash dividend distribution is September 22, 2023.
お知らせ • Jun 28Formosa Laboratories, Inc. Approves Independent Directors ElectionsFormosa Laboratories, Inc. announced at annual shareholders meeting held on June 27, 2023, the shareholders approved election of Chaung,Tza-Zen and Chang,Ting-Jung as independent directors of the company.
Valuation Update With 7 Day Price Move • May 02Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$91.50, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 57% over the past three years.
Reported Earnings • Mar 17Full year 2022 earnings released: EPS: NT$3.40 (vs NT$10.92 in FY 2021)Full year 2022 results: EPS: NT$3.40 (down from NT$10.92 in FY 2021). Revenue: NT$3.77b (up 20% from FY 2021). Net income: NT$409.4m (down 67% from FY 2021). Profit margin: 11% (down from 40% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 9 highly experienced directors. 1 independent director (6 non-independent directors). Independent Director Zhe Ren Zhuang was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 13Third quarter 2022 earnings released: EPS: NT$4.09 (vs NT$3.20 loss in 3Q 2021)Third quarter 2022 results: EPS: NT$4.09 (up from NT$3.20 loss in 3Q 2021). Revenue: NT$1.02b (up 49% from 3Q 2021). Net income: NT$492.1m (up NT$876.6m from 3Q 2021). Profit margin: 48% (up from net loss in 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
Reported Earnings • Aug 17Second quarter 2022 earnings released: NT$0.07 loss per share (vs NT$6.86 profit in 2Q 2021)Second quarter 2022 results: NT$0.07 loss per share (down from NT$6.86 profit in 2Q 2021). Revenue: NT$838.2m (up 1.3% from 2Q 2021). Net loss: NT$8.53m (down 101% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 17% per year.
Upcoming Dividend • Jul 20Upcoming dividend of NT$2.00 per shareEligible shareholders must have bought the stock before 27 July 2022. Payment date: 25 August 2022. Trailing yield: 4.2%. Lower than top quartile of Taiwanese dividend payers (6.8%). Higher than average of industry peers (2.9%).
Reported Earnings • May 16First quarter 2022 earnings released: NT$3.33 loss per share (vs NT$9.84 profit in 1Q 2021)First quarter 2022 results: NT$3.33 loss per share (down from NT$9.84 profit in 1Q 2021). Revenue: NT$834.9m (up 13% from 1Q 2021). Net loss: NT$400.4m (down 138% from profit in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Apr 27Price target decreased to NT$55.00Down from NT$65.00, the current price target is provided by 1 analyst. New target price is 15% below last closing price of NT$64.90. Stock is up 13% over the past year. The company posted earnings per share of NT$10.92 last year.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 9 highly experienced directors. 1 independent director (6 non-independent directors). Independent Director Zhe Ren Zhuang was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improved over the past weekAfter last week's 18% share price gain to NT$68.10, the stock trades at a trailing P/E ratio of 6.6x. Average forward P/E is 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 61% over the past three years.
Reported Earnings • Mar 13Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: NT$10.92 (up from NT$3.79 in FY 2020). Revenue: NT$3.14b (up 2.2% from FY 2020). Net income: NT$1.25b (up 212% from FY 2020). Profit margin: 40% (up from 13% in FY 2020). The increase in margin was primarily driven by lower expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 12Third quarter 2021 earnings released: NT$3.20 loss per share (vs NT$0.93 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: NT$689.7m (down 15% from 3Q 2020). Net loss: NT$384.6m (down 481% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 09Second quarter 2021 earnings released: EPS NT$6.86 (vs NT$4.99 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: NT$827.3m (up 5.0% from 2Q 2020). Net income: NT$744.6m (up 39% from 2Q 2020). Profit margin: 90% (up from 68% in 2Q 2020). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Jul 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to NT$66.80, the stock trades at a trailing P/E ratio of 4.6x. Average forward P/E is 21x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 30% over the past three years.
Valuation Update With 7 Day Price Move • Jun 17Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to NT$83.60, the stock trades at a trailing P/E ratio of 5.8x. Average forward P/E is 20x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 60% over the past three years.
Valuation Update With 7 Day Price Move • May 21Investor sentiment improved over the past weekAfter last week's 28% share price gain to NT$74.40, the stock trades at a trailing P/E ratio of 5.1x. Average forward P/E is 20x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 41% over the past three years.
Reported Earnings • May 15First quarter 2021 earnings released: EPS NT$9.84 (vs NT$1.03 loss in 1Q 2020)First quarter 2021 results: Revenue: NT$736.3m (up 11% from 1Q 2020). Net income: NT$1.07b (up NT$1.17b from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
分析記事 • Apr 19Here's Why Formosa Laboratories (TPE:4746) Has A Meaningful Debt BurdenHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Valuation Update With 7 Day Price Move • Mar 23Investor sentiment improved over the past weekAfter last week's 15% share price gain to NT$56.60, the stock trades at a forward P/E ratio of 74x. Average forward P/E is 22x in the Pharmaceuticals industry in Taiwan. Total loss to shareholders of 2.9% over the past three years.
分析記事 • Mar 16Does Formosa Laboratories, Inc.'s (TPE:4746) Weak Fundamentals Mean A Downturn In Its Stock Should Be Expected?Formosa Laboratories' (TPE:4746) stock is up by 9.9% over the past three months. However, in this article, we decided...
Reported Earnings • Mar 06Full year 2020 earnings released: EPS NT$3.78 (vs NT$0.12 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$3.08b (up 11% from FY 2019). Net income: NT$400.0m (up NT$388.4m from FY 2019). Profit margin: 13% (up from 0.4% in FY 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Feb 22Investor sentiment improved over the past weekAfter last week's 16% share price gain to NT$54.80, the stock is trading at a trailing P/E ratio of 12.3x, up from the previous P/E ratio of 10.6x. This compares to an average P/E of 18x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders over the past three years are 8.7%.
Is New 90 Day High Low • Feb 19New 90-day high: NT$52.80The company is up 6.0% from its price of NT$49.90 on 20 November 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 13% over the same period.
分析記事 • Feb 08What Type Of Returns Would Formosa Laboratories'(TPE:4746) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?The main aim of stock picking is to find the market-beating stocks. But in any portfolio, there will be mixed results...
分析記事 • Jan 11Formosa Laboratories (TPE:4746) Is Making Moderate Use Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Dec 13Formosa Laboratories's (TPE:4746) Earnings Are Growing But Is There More To The Story?Many investors consider it preferable to invest in profitable companies over unprofitable ones, because profitability...
Is New 90 Day High Low • Dec 07New 90-day low: NT$47.80The company is down 10.0% from its price of NT$53.20 on 08 September 2020. The Taiwanese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 7.0% over the same period.
Reported Earnings • Nov 15Third quarter 2020 earnings released: EPS NT$0.93The company reported a soft third quarter result with weaker earnings and profit margins, although revenues were improved. Third quarter 2020 results: Revenue: NT$814.7m (up 3.2% from 3Q 2019). Net income: NT$100.9m (down 41% from 3Q 2019). Profit margin: 12% (down from 22% in 3Q 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 13% per year whereas the company’s share price has fallen by 11% per year.
Is New 90 Day High Low • Oct 28New 90-day low: NT$48.40The company is down 3.0% from its price of NT$50.10 on 30 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period.
